These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Placental Transfer of Canakinumab in a Patient with Muckle-Wells Syndrome. Egawa M; Imai K; Mori M; Miyasaka N; Kubota T J Clin Immunol; 2017 May; 37(4):339-341. PubMed ID: 28386702 [No Abstract] [Full Text] [Related]
18. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan. Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882 [TBL] [Abstract][Full Text] [Related]
19. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692 [TBL] [Abstract][Full Text] [Related]
20. Muckle-Wells syndrome: individualized, reflare-guided dosing of the orphan drug canakinumab. Mueller SM; Itin P; Haeusermann P Skinmed; 2013; 11(2):80-3. PubMed ID: 23745225 [No Abstract] [Full Text] [Related] [Next] [New Search]